THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Novel Genetic Variants are Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of SCL1A3 and EPHB2

Citation for published version:

Nielson, CM, Liu, C-T, Smith, AV, Ackert-Bicknell, CL, Reppe, S, Johanna, J, Wassel, C, Register, TC, Oei, L, Alonso Lopez, N, Oei, EH, Parimi, N, Samelson, EJ, Nalls, MA, Zmuda, J, Lang, T, Bouxsein, M, Latourelle, J, Claussnitzer, M, Siggeirsdottir, K, Srikanth, P, Lorentzen, E, Vandenput, L, Langefeld, C, Raffield, L, Terry, G, Cox, AJ, Allison, MA, Criqui, MH, Bowden, D, Ikram, MA, Mellström, D, Karlsson, MK, Carr, J, Budoff, M, Phillips, C, Cupples, LA, Chou, W-C, Myers, RH, Ralston, SH, Gautvik, KM, Cawthon, PM, Cummings, S, Karasik, D, Rivadeneira, F, Gudnason, V, Orwoll, ES, Harris, TB, Ohlsson, C, Kiel, DP & Hsu, Y-H 2016, 'Novel Genetic Variants are Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of SCL1A3 and EPHB2', *Journal of Bone and Mineral Research*, vol. 31, no. 12. <https://doi.org/10.1002/jbmr.2913>

Digital Object Identifier (DOI):

[10.1002/jbmr.2913](https://doi.org/10.1002/jbmr.2913)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of Bone and Mineral Research

Publisher Rights Statement:

Author's final peer-reviewed manuscript as accepted for publication

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Novel genetic variants are associated with increased vertebral volumetric BMD, reduced vertebral fracture risk, and increased expression of *SCLIA3* and *EPHB2*[†]

Carrie M Nielson,^{1*} Ching-Ti Liu,² Albert V Smith,^{3,4} Cheryl L Ackert-Bicknell,⁵ Sjur Reppe,⁶⁻⁸ Jakobsdottir, Johanna,³ Christina Wassel,⁹ Thomas C Register,¹⁰ Ling Oei,^{11,12} Nerea Alonso Lopez,¹³ Edwin H Oei,¹⁴ Neeta Parimi,¹⁵ Elizabeth J Samelson,¹⁶ Mike A Nalls,¹⁷ Joseph Zmuda,¹⁸ Thomas Lang,¹⁹ Mary Bouxsein,²⁰ Jeanne Latourelle,²¹ Melina Claussnitzer,²²⁻²⁴ Kristin Siggeirsdottir,²⁵ Priya Srikanth,¹ Erik Lorentzen,²⁶ Liesbeth Vandenput,²⁷ Carl Langefeld,²⁸ Laura Raffield,^{29,30} Greg Terry,³¹ Amanda J Cox,³² Matthew A Allison,³³ Michael H Criqui,³³ Don Bowden,^{32,34,35} M Arfan Ikram,³⁶ Dan Mellström,²⁷ Magnus K Karlsson,³⁷ John Carr,³¹ Matthew Budoff,³⁸ Caroline Phillips,¹⁷ L Adrienne Cupples,² Wen-Chi Chou,²³ Richard H Myers,²¹ Stuart H Ralston,³⁹ Kaare M Gautvik,^{8,40} Peggy M Cawthon,^{15,41} Steven Cummings,¹⁵ David Karasik,^{16,42} Fernando Rivadeneira,^{36,43} Vilmundur Gudnason,^{3,4} Eric S Orwoll,⁴⁴ Tamara B Harris,¹⁷ Claes Ohlsson,²⁷ Douglas P Kiel,^{16,22*} and Yi-Hsiang Hsu^{16,23,45*}

¹School of Public Health, Oregon Health & Science University, Portland, OR, USA

²Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

³Icelandic Heart Association, Kópavogur, Iceland

⁴Faculty of Medicine, University of Iceland, Reykjavík, Iceland

⁵Department of Orthopaedics and Rehabilitation, University of Rochester, Rochester, NY, USA

⁶Department of Medical Biochemistry, Oslo University Hospital, Ullevål, Oslo, Norway

⁷Lovisenberg Diakonale Hospital, Oslo, Norway

⁸Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

⁹Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA

¹⁰Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA

¹¹Internal Medicine, Erasmus MC, Rotterdam, The Netherlands

¹²Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), Leiden, The Netherlands

¹³Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK

¹⁴Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

¹⁵California Pacific Medical Center Research Institute, San Francisco, CA, USA

¹⁶Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA

¹⁷National Institute on Aging (NIA), National Institutes of Health, Bethesda, MD, USA

[†]This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/jbmr.2913]

Additional Supporting Information may be found in the online version of this article.

Initial Date Submitted April 13, 2016; Date Revision Submitted June 22, 2016; Date Final Disposition Set July 8, 2016

Journal of Bone and Mineral Research
This article is protected by copyright. All rights reserved
DOI 10.1002/jbmr.2913

- ¹⁸Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
- ¹⁹Department of Radiology, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
- ²⁰Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA, USA
- ²¹Department of Neurology, Boston University, Boston, MA, USA
- ²²Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA, USA
- ²³Broad Institute of MIT and Harvard, Cambridge, MA, USA;
- ²⁴Technical University Munich, Munich, Germany
- ²⁵Imaging, Icelandic Heart Association, Kópavogur, Iceland
- ²⁶Department of Bioinformatics, Gothenburg University, Gothenburg, Sweden
- ²⁷Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- ²⁸Public Health Sciences Wake Forest School of Medicine, Winston-Salem, NC, USA
- ²⁹Center for Human Genomics and Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
- ³⁰Center for Human Genomics and Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
- ³¹Department of Radiology & Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA
- ³²Center for Diabetes Research, Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA
- ³³Department of Family Medicine and Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA
- ³⁴Internal Medicine/Endocrinology, Wake Forest School of Medicine, Winston-Salem, NC, USA
- ³⁵Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
- ³⁶Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands
- ³⁷Department of Orthopaedics and Clinical Sciences, Malmö University Hospital, Lund University, Malmö, Sweden
- ³⁸Los Angeles Biomedical Research Institute, Torrance, CA, USA
- ³⁹Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
- ⁴⁰Lovisenberg Diakonale Hospital, Oslo, Norway
- ⁴¹Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
- ⁴²Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel
- ⁴³Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
- ⁴⁴Division of Endocrinology, Oregon Health & Science University, Portland, OR, USA
- ⁴⁵Molecular and Integrative Physiological Sciences, Harvard School of Public Health, Boston, MA, USA

Address correspondence to: Carrie M Nielson, MPH, PhD, School of Public Health, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, CR113, Portland, OR 97239, USA. E-mail: nielsoca@ohsu.edu

*CMN, DPK, and Y-HH contributed equally to this work.

ABSTRACT

Genome-wide association studies (GWAS) have revealed numerous loci for areal bone mineral density (aBMD). We completed the first GWAS meta-analysis (N=15,275) of lumbar spine volumetric BMD (vBMD) measured by quantitative computed tomography (QCT), allowing for examination of the trabecular bone compartment. SNPs that were significantly associated with vBMD were also examined in two GWAS meta-analyses to determine associations with morphometric vertebral fracture in (N=21,701) and clinical vertebral fracture (N=5,893). Expression QTL analyses of iliac crest biopsies were performed in 84 postmenopausal women, and murine osteoblast expression of genes implicated by eQTL or by proximity to vBMD-associated SNPs was examined. We identified significant vBMD associations with five loci, including 1p36.12, containing *WNT4* and *ZBTB40*; 8q24, containing *TNFRSF11B*; and 13q14, containing *AKAP11* and *TNFSF11*. Two loci (5p13 and 1p36.12) also contained associations with radiographic and clinical vertebral fracture, respectively. In 5p13, rs2468531 (minor allele frequency [MAF]=3%) was associated with higher vBMD ($\beta = 0.22$, $p = 1.9 \times 10^{-8}$) and decreased risk of radiographic vertebral fracture (OR = 0.75; false discovery rate [FDR] $p = 0.01$). In 1p36.12, rs12742784 (MAF=21%) was associated with higher vBMD ($\beta = 0.09$, $p = 1.2 \times 10^{-10}$) and decreased risk of clinical vertebral fracture (OR = 0.82; FDR $p = 7.4 \times 10^{-4}$). Both SNPs are non-coding and were associated with increased mRNA expression levels in human bone biopsies: rs2468531 with *SLC1A3* ($\beta = 0.28$, FDR $p = 0.01$, involved in glutamate signaling and osteogenic response to mechanical loading) and rs12742784 with *EPHB2* ($\beta = 0.12$, FDR $p = 1.7 \times 10^{-3}$, functions in bone-related ephrin signaling). Both genes are expressed in murine osteoblasts. This is the first study to link *SLC1A3* and *EPHB2* to clinically relevant vertebral osteoporosis phenotypes. These results may help elucidate vertebral bone biology and novel approaches to reducing vertebral fracture incidence.

This article is protected by copyright. All rights reserved

KEY WORDS: BONE QCT/ μ CT; ANALYSIS/QUANTITATION OF BONE; OSTEOPOROSIS; DISEASES AND DISORDERS OF/RELATED TO BONE; GENERAL POPULATION STUDIES; EPIDEMIOLOGY, HUMAN ASSOCIATION STUDIES; GENETIC RESEARCH; FRACTURE RISK ASSESSMENT; PRACTICE/POLICY-RELATED ISSUES

INTRODUCTION

Vertebral osteoporosis and fracture are substantial sources of pain, height loss, and mobility limitation in older adults(1). Not only has the burden of these conditions increased with the aging of populations, but the age-specific incidence of vertebral fracture has risen or remained steady even as the incidence of hip and other osteoporotic fractures has declined.(2-4) Risk of fracture correlates with lower vertebral bone mineral density (BMD)(5) that declines with age, leaving the bone susceptible to compression and deformation even in the absence of traumatic force.

Both vertebral BMD and fracture are heritable,(6) and multiple genetic loci have been associated with BMD as determined by dual x-ray absorptiometry (DXA) through large-scale GWAS meta-analyses.(7,8) Far fewer loci – either from BMD candidate genes or from GWAS — have been linked to fracture risk, even in large samples(9,10). This is likely due to several factors, including the multifactorial causation of fracture, heterogeneity of fracture risk by skeletal sites, and the inability of DXA BMD to completely define bone strength and fracture risk.

Vertebral bone is unique in that its source of strength comes to a large extent from the trabecular compartment, with relatively little cortical area compared to other load-bearing skeletal sites. Quantitative computed tomography (CT) of the vertebrae allows for volumetric BMD measures of the trabecular compartment specifically, which are more strongly associated with vertebral fracture than areal BMD measures.(11) Areal BMD measured by DXA is confounded by bone size. In contrast with DXA, CT-based measurements of the spine allow for exclusion of vertebral elements and artifacts, including osteophytic or extra-skeletal calcification that is common in older adults.(12,13) For these reasons, we undertook a GWAS meta-analysis of quantitative CT-based volumetric BMD in the lumbar spine in older men and women, and we evaluated the resulting associations in separate meta-analyses of vertebral fracture.

METHODS

Study Design and Participants

Cohort design and characteristics are described in Supplemental Table 1.

Discovery studies: Six cohorts of men and women of European descent with CT imaging of the L2 or L3 spine were included in a discovery meta-analysis of trabecular volumetric BMD (vBMD, N=12,287). Discovery cohorts included Age Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik)(14), Framingham Osteoporosis Study(6,15), Family Heart Study, Health Aging and Body Composition (Health ABC), Multi-Ethnic Study of Atherosclerosis (MESA)(16), and

Osteoporotic Fractures in Men (MrOS)(17). Except for Health ABC, the cohorts also had an integral vBMD (N=11,080) phenotype at the same lumbar vertebra. All participants were adults, and the mean age in each cohort ranged from 52 to 76 years (Supplemental Table 1).

Replication studies: Replication of trabecular vBMD associations were done *in silico* in the Diabetes Heart Study (DHS, N=967) and with de-novo genotyping on selected SNPs in an additional sample from the AGES-Reykjavik cohort (N=2,020).

Fracture studies: Two of the discovery cohorts (Framingham and MrOS) and five additional cohorts (MrOS-Sweden, Rotterdam I-III, Study of Osteoporotic Fractures [SOF]) contributed to the evaluation of trabecular vBMD-associated loci for their association with radiographic vertebral fracture (N=21,701; 23% fracture cases).

Lumbar Spine CT Phenotypes

CT scans of the spine provided vBMD phenotypes at either L2 or L3 (Figure 1). In cohorts with vBMD measured at adjacent levels, correlations were high ($r=0.89-0.93$). CT scanners and software used in each cohort are listed in Supplemental Table 1. In MESA, CT data were analyzed using Image Analysis Volumetric Software, and the remaining cohorts were analyzed using software developed by one author (TL).(18) In order to ensure regions of interest were defined consistently across cohorts, two authors (TL and MB) evaluated phenotype definitions. The tissue density of the analyzed volume calibrated to units of equivalent concentration of hydroxyapatite in g/cm^3 yielded the BMD values. The following two BMD phenotypes were analyzed:

Trabecular volumetric BMD (vBMD) is the average density in g/cm^3 of all the voxels contained within the boundary of the trabecular region. This measure was calculated from a single slice of the region encompassing most of the trabecular bone in the vertebral body (Figure 1).

Integral vBMD is the average density in g/cm^3 of all the voxels contained within the periosteal edge of the vertebral body, excluding all of the posterior elements (Figure 1).

Vertebral Fracture Phenotypes

Two separate fracture GWAS meta-analyses were conducted on non-overlapping population samples. Radiographic vertebral fracture is often asymptomatic and was evaluated by imaging in cohort studies of older men and women (described below). On the other hand, clinical vertebral fracture was

defined (as described in the attached manuscript by Lopez *et al.*) by signs and symptoms such as back pain, height loss, and kyphosis and was confirmed by imaging.

Radiographic vertebral fracture: These studies included prevalent and incident fracture evaluated from T4 to L4. Prevalent radiographic vertebral fracture was defined for each cohort as described in Supplemental Table 1. Prevalent vertebral fracture was defined by Genant's scale(19) or by using vertebral body height ratios $>3SD$ (20,21), evaluated by visual semi-quantitative readings or quantitative assessments with review by a radiologist. In three cohorts (MrOS(22), Rotterdam I and II), incident radiographic vertebral fracture was also included in the case definition. Between 15% and 22% of each cohort were cases.

Clinical vertebral fracture: Nine clinic- or population-based case-control or cohort studies were included in the GWAS of this phenotype. All participants were postmenopausal women age 45 or older from Europe or Australia. Cases were matched with controls from the same geographical region or same ethnic background.

Genotyping and Imputation

Genome-wide genotyping was followed by imputation of non-genotyped SNPs up to 2.7 million SNPs using the HapMap II reference panels. Details of each cohort's genotyping and imputation methods are provided in Supplemental Table 2. Replication genotyping for 13 SNPs in the AGES cohort was done using TaqMan at LGC Genomics.

Statistical Analysis

Association analyses were performed in each study first and then meta-analyses were applied to combine results from each study. Within each study, a z-score transformation of BMD phenotypes was applied. A general linear regression model with the additive genetic effect was applied to test for association between each BMD phenotype (Z-score) and each autosomal SNP. In the regression model, we adjusted for age, age², weight (kg), and principal components for ancestral genetic background and study specific covariates (such as study site). In mixed-sex cohorts, sex was included as an adjustment variable in the regression model. Sex-stratified results were also provided. In the Framingham Osteoporosis Study and the Family Heart Study, a linear mixed effects model with within-family correlations as a random effect was used to account for relatedness among participants. In the Diabetes Heart Study, a random effects model was implemented using Sequential Oligogenic Linkage

Analysis Routines (SOLAR) version 6.3.4 (Texas Biomedical Research Institute, San Antonio, TX, USA) as previously described (23,24). The kinship coefficient matrix used was verified by the genotypic data via the software KING. The fixed-effect inverse-variance meta-analyses were performed by two authors (YH and CN) independently. Meta-analysis results were filtered by sample size (< half of the total sample size), number of studies with available results (< 3 cohort studies), overall MAF (< 1%) and the heterogeneity test across studies ($I^2 \geq 50$ or p-values for heterogeneity χ^2 test $q \leq 5 \times 10^{-5}$). Genome-wide significance (GWS) level was defined as p-value $< 5 \times 10^{-8}$, and suggestive significance level was defined as $p < 5 \times 10^{-6}$ after adjusting for genomic control λ_{GC} value within each cohort and after meta-analysis. Double genomic control was applied to the integral vBMD GWAS after observing an elevated λ_{GC} value. Q-Q and Manhattan plots were generated in R 3.2.2 using plyr and qqman packages (Supplemental Figures 1 and 2). For GWS and suggestive SNPs, effect sizes were evaluated for heterogeneity between sexes using fixed-effect inverse-variance meta-analysis.

Conditional associations: To identify whether SNPs that were associated with trabecular vBMD or integral vBMD were independent from (not in LD with) SNPs that were reported to be associated with DXA BMD at the lumbar spine,(8) we performed a conditional analysis using the GCTA (Genome-wide Complex Trait Analysis) tool package.(25,26) For GWS and suggestive loci, we conditioned on reported BMD GWAS SNPs (associated with lumbar spine BMD measured by DXA). We selected SNPs for replication genotyping that were associated with CT BMD (trabecular vBMD or integral vBMD) independently from SNPs associated with DXA BMD based on conditional analyses. After genotype quality control, thirteen SNPs were available for inclusion in meta-analyses of discovery and replication.

Association with radiographic vertebral fracture: The most significant SNP at each GWS or suggestive trabecular vBMD locus (n=12) was evaluated for its association with radiographic vertebral fracture using logistic regression, with results combined across cohorts using fixed-effect inverse-variance meta-analysis. In each cohort, adjustments for age, height, and weight were performed. In mixed-sex cohorts, sex adjustment was also included. In addition, results for each of the 12 SNPs were examined in an independent meta-analysis of clinical vertebral fracture (N=5,893, Lopez *et al.*, submitted manuscript attached to this submission for your review). False-discovery rate p-values were calculated, and the direction of effect relative to that for trabecular vBMD was used to evaluate consistency across phenotypes (e.g., an OR>1 for fracture is consistent with a negative β for trabecular vBMD).

Expression Quantitative Trait Loci (eQTLs) Analysis

We conducted cis-expression quantitative trait locus (eQTL) analysis within a 2Mb flanking region (1Mb upstream and 1 Mb downstream) of each of the top SNPs to evaluate whether they influence transcript levels of genes in human pelvic crest bone biopsies(27) and human primary osteoblasts.(28) Expression experiments in human whole bone biopsies and human primary osteoblasts were conducted in different study samples. For details of genotyping and microarray expression profiling, see Supplemental Methods. For eQTL analyses, a linear regression model with the additive genetic effect was used. We adjusted for age, weight, cigarette smoking and genetic ancestry in the regression model. Locus-wide statistical significance was defined as false discovery rate (FDR) Q-values < 0.05 in each locus.

Primary Murine Osteoblasts

Gene expression profiles of six candidate genes near genome-wide associated SNPs were examined in primary mouse osteoblasts undergoing differentiation. These data have been described in detail previously(29) and are freely available from the Gene Expression Omnibus (GSE54461). For details, see Supplemental Methods.

In-silico Annotation and Enrichment Analyses

Since all GWS and suggestive SNPs were non-coding (either intronic and intergenic SNPs), as were all SNPs in high LD with them, we annotated potential regulatory functions of those SNPs based on experimental epigenetic evidence including chromatin states, DNase hypersensitive sites, histone modifications, phylogenetic conservation, altered regulatory motifs for transcription factor binding sites in human tissues, primary cells and cell lines from the ENCODE Project and the Roadmap Epigenomics Project(30,31). This was done by searching the HaploReg4 web browser.(32) Position weight matrices (PWMs) of a motif sequence were scored for instances that passed a threshold of $p < 4 \times 10^{-7}$. Only instances where a motif in the sequence passed the threshold of a PWM in either the reference or the alternate genomic sequence with variable nucleotide(s) (thus changing the PWM score) were considered. The enhancer and promoter states were obtained by ChromHMM(33) and were visualized using the WashU Epigenome Browser (<http://epigenomegateway.wustl.edu/>). To evaluate whether top-associated SNPs were enriched with regulatory elements in specific tissues (such as bone relevant tissues, including primary osteoblast, bone-marrow-derived stem cell, or mesenchymal progenitor cells available in the ENCODE and the Roadmaps Epigenomics Project), a

hypergeometric test was performed and permutation was used to estimate enrichment p-values. Since our imputation was based on the reference panel that is not generated by whole genome sequencing (international HapMap Project Phase II reference panel), we expected that our top associated SNPs may predominantly serve only as surrogate markers that are in high LD with the un-genotyped and un-imputed functional SNPs that are responsible for GWAS signals. Therefore, we extended our *in-silico* functional annotation and enrichment analysis to those common SNPs (MAF > 1% based on 1000 Genomes Project Phase I version 3 CEU references) that are in high LD ($r^2 > 0.8$ based on 1000 Genomes Project Phase I version 3 CEU references) with the most significant SNP in each locus.

RESULTS

BMD and Fracture Associations

Five loci had genome-wide significant (GWS, $p < 5 \times 10^{-8}$) associations with trabecular volumetric BMD (vBMD) in the meta-analysis of discovery (6 cohort studies) and replication cohorts (2 cohort studies, combined $N=15,275$). These included four loci marked by common SNPs (MAF $\geq 5\%$) located in 1p36.12 (near *WNT4*, *ZBTB40*), 1p43 (*GREM2*), 8q24 (*TNFRSF11B*), and 13q14 (*TNFSF11*, Table 1). All except for *GREM2* have been previously associated with lumbar spine areal BMD. In addition, in the 5p13 locus, which has not previously been linked to lumbar spine BMD, the most significantly associated SNP with trabecular vBMD was rs2468531 (MAF = 3%). All GWS SNPs were intronic or intergenic (Supplemental Figure 3). There was no significant heterogeneity of effect sizes between sexes for these SNPs (Supplemental Figure 4). All GWS SNPs associated with trabecular vBMD were also strongly associated with integral vBMD and had similar effect sizes, although not all of the trabecular vBMD GWAS SNPs achieved genome-wide significance for integral vBMD, perhaps because of the smaller sample size with integral vBMD measurements (Supplemental Table 3). An additional 6 loci had common SNPs with suggestive-significant associations ($5 \times 10^{-8} < p < 5 \times 10^{-6}$) with trabecular vBMD, and only one of these (6q25) reached a suggestive significance level for integral vBMD (Supplemental Table 3). An additional 9 loci had SNPs that were suggestively associated with integral vBMD, though only 2 were suggestive after double GC adjustment (Supplemental Table 3). Among them, the most significantly associated SNP, rs3786178 (MAF = 2%) near *CTIF* on 18q21.2, had a relatively strong association (standardized $\beta = 0.19$, $p = 1.86 \times 10^{-6}$).

Among SNPs associated with trabecular vBMD or integral vBMD (listed in Table 1) with $p < 5 \times 10^{-6}$, only rs2468531 (5p13, near *SLCIA3*) was found to be associated with radiographic vertebral fracture after correction for multiple testing (odds ratio [OR] = 0.75 per minor allele, FDR p-value = 0.01, Table 2, Figure 2). The same SNP was nominally associated with clinical vertebral fracture (OR

= 0.66, $p = 0.01$, see the Lopez *et al.* manuscript attached to this submission, but FDR $p = 0.07$).

Among SNPs associated with trabecular vBMD (listed in Table 1), the GWAS SNP rs12742784 near *ZBTB40* was associated with clinical vertebral fracture (OR = 0.82, FDR $p = 7.4 \times 10^{-4}$). Although SNPs at other loci (*GREM2*, *C6orf97*, *ATP2B1*) were nominally significantly associated with vertebral fracture, no other ORs were nearly as strong as for rs2468531 or rs12742784 (Table 2).

***cis*-Expression Quantitative Trait Loci (*cis*-eQTLs) in Human Bone Biopsies**

The *cis*-eQTL results of the whole bone biopsies are shown in Table 3. For genome-wide significant SNPs, we found two significant eQTLs after multiple testing correction. First, SNP rs12742784 in the 1p36.12 locus was associated with increased expression of *EPHB2*, about 355 kb downstream ($\beta = 0.12$, FDR $p = 1.72 \times 10^{-3}$), but was only marginally associated ($p = 0.08$) with *ZBTB40*, the nearest gene in this GWAS locus (about 96 kb downstream). The other significant *cis*-eQTL finding was for SNP rs2468531 in the 5p13 locus, which was associated with increased expression of *SLC1A3*, 126 kb downstream from the associated SNP ($\beta = 0.28$, FDR $p = 0.01$). A suggestive SNP, rs2941584, was associated with *EML6* expression in the 2p21 locus (FDR $p = 0.04$); and a suggestive SNP rs7301013 with *WNT5B* expression in the 12p13.3 locus (FDR $p = 0.01$). In most cases, the most significantly associated *cis*-eQTL gene in each locus was not the gene nearest to the top associated SNP, a phenomenon also observed in other studies(34). *CCDC91* was filtered out due to low signal values in the microarray.

Expression in Mouse Osteoblasts

Ten of the eleven genes located near a trabecular vBMD locus or implicated through eQTL analysis were expressed during murine osteoblastogenesis, and each presented with a unique level and/or pattern of expression. *EphB2* maintained a consistent level of expression over time, whereas *Slc1a3* expression rose rapidly through the period of rapid cell proliferation and reached a plateau coincident with a phase associated with increased expression of extracellular matrix genes (~day 8-10, Supplemental Figure 5). Of the two genes near 1q43, *Grem2* expression was extremely high during the period of cell culture associated with rapid growth and cell division. Expression of this gene decreased and entered a steady state plateau at about day 8 post differentiation. Like *Grem2*, *Fmn2* showed a pattern of decreasing expression during osteoblastogenesis; however, expression of this gene was very low at all points examined. Both *Akap11* and *Zbtb40* demonstrated constant expression during osteoblast maturation (Supplemental Figure 5).

***In-silico* Annotation of Non-Coding SNPs and of SNPs in LD with the Top Associated SNPs**

Evaluation of whether the top-associated SNPs (from Table 1) were enriched with regulatory elements in specific tissues showed the most significant enrichment for the cortex derived primary cultured neurospheres (E053) with enrichment p-value = 9.56×10^{-3} . We observed 3 SNPs (out of 12) overlapping with regulatory elements in the cortex neurospheres (ENCODE, Supplemental Tables 4 and 5), compared to the 0.5 expected SNPs overlapping with regulatory elements in the same cell type if we randomly select 12 SNPs with the same MAF and LD pattern across the whole genome. After multiple testing corrections by FDR, the enrichment in the cortex neurospheres became non-significant.

Two common nonsynonymous SNPs were found to be in LD with the top associated SNPs. SNP rs2073618 (N3K) (discovery p-value = 1.41×10^{-6}) in *TNFRSF11B* is in high LD ($r^2=0.88$) with rs1485303, and SNP rs35737760 (D859E) in *CACNA1E* is in high LD with SNP rs7301013 that was suggestive for integral vBMD. However, both variants were predicted not to affect protein function due to the corresponding amino acid substitution based on the conservation-based SIFT package and were predicted to be benign by PolyPhen-2. All common SNPs in high LD with top associated SNPs in all other loci were either intronic or intergenic. Twelve of the 21 loci with GWS or suggestive trabecular vBMD or integral vBMD associations had SNPs in LD that were located in either predicted enhancer or promoter regions in one of the three bone-relevant cell types: osteoblast primary cells, mesenchymal stem cell derived chondrocyte cultured cells, and bone marrow derived mesenchymal cultured cells (E129, E049 and E026, Supplemental Table 5). These included intronic or intergenic SNPs in the GWS trabecular vBMD loci near *GREM2*, *TNFRSF11B*, and *TNFSF11*, as well as the 5p13 locus. Of note, the *GREM2* locus (1q43) has quiescent annotations across an abundance of cell types except for 2 SNPs, rs1414660 (r^2 for LD with top vBMD SNP = 0.87; discovery p-value = 2.01×10^{-10}) and rs9659023 (not analyzed), which are both located in an enhancer region that is specifically active in bone marrow derived mesenchymal cells, osteoblasts and other mesenchymal cells, suggesting a cell-type specific gene regulation in those bone-relevant cells. The rs1414660 regulatory sequence is under evolutionary constraint, as estimated by GERP and SiPhy (http://www.broadinstitute.org/mammals/haploreg/detail_v4.1.php?query=&id=rs1414660). Furthermore, the rs1414660 intronic single nucleotide change was predicted to perturb conserved regulatory motifs for bone-relevant transcription factors, such as CEBPa, CEBPb and others (Supplemental Table 6). The 5p13 locus is quiescent except for a region surrounding the indel rs148073475 (http://www.broadinstitute.org/mammals/haploreg/detail_v4.1.php?query=&id=rs148073475). To

evaluate whether these 12 SNPs in LD with variants are specifically located in enhancer regulatory regions for three bone-relevant cells we tested for enrichment in regulatory regions in tissues other than bone relevant tissues. We performed hypergeometric tests in 127 cell types and tissues from the Roadmap Epigenomics Project but did not find significant enrichment, suggesting that these selected SNPs are enriched only in bone-specific gene regulatory regions.

DISCUSSION

Through these meta-analyses of vertebral trabecular vBMD and fracture, we identified two loci associated with lumbar spine BMD, vertebral fracture, and human bone expression of genes that were also expressed in mouse osteoblasts. One is a novel BMD locus, at 5p13, and the minor alleles of the most significantly associated SNPs had a lower frequency (3%), stronger positive associations with trabecular vBMD ($\beta = 0.22$), and lower risk of fracture (OR = 0.75) than did other variants associated with BMD or fracture in this study. Cis-eQTL analyses in human bone and mouse osteoblast expression studies suggest that the *SLC1A3* gene, which is ~126 kb upstream of SNP rs2468531, may be the gene in this locus involved in bone modeling/remodeling. Common variants in another locus, 1p36.12, were significantly associated with trabecular vBMD, fracture (clinical vertebral OR: 0.82, FDR $p = 7.4 \times 10^{-4}$) and expression of *EPHB2*, providing an explanation for the associations with BMD phenotypes consistently reported in this region(8,35-37). This is the first study to link *EPHB2* expression to vertebral phenotypes in humans. The finding that these loci are associated with both vertebral trabecular BMD and vertebral fracture reinforces their clinical importance. Our expression studies suggest a regulatory function for the causal variants underlying these SNP associations.

***SLC1A3*:** Previous studies have reported that the *SLC1A3* gene is involved in glutamate signaling necessary for osteogenic response to mechanical loading.(38) *SLC1A3* (aka *GLAST* or *EAAT1*) is a glutamate transporter expressed in human as well as rat and mouse osteoblasts and osteocytes, discovered through its down-regulation in osteocytes in response to osteogenic mechanical loading(39). *SLC1A3* has been found to be expressed in most human tissues/cells, especially in brain and neurons. Although a *Slc1a3* mouse knock-out showed no differences in multiple femoral bone phenotypes through age 6 months,(40) there has been no examination of either vertebral bone phenotypes or of aged mice in such a knockout. These are important distinctions, as *Slc1a3* knockout effects on another phenotype have been shown to depend on advanced age,(41) and axial and appendicular skeletal regions are known to have distinct patterns of development and regulation over the course of development (e.g., (42-44)).

SLC1A3 associations have not been reported to be genome-wide significantly associated with aBMD in any previous study. In the most recent lumbar spine aBMD GWAS meta-analysis, the most significant SNP in this locus was rs2468531 (MAF=4.8%, $\beta = 0.077$, $p = 7.4 \times 10^{-3}$) (29). That aBMD GWAS meta-analysis had much larger sample size and included many of the participating studies in our CT GWAS meta-analysis. It is unclear whether the difference in phenotype or underlying population differences contributed to this discrepancy. Previously reported cell and animal model evidence for *SLC1A3* suggests its biological function in bone physiology may interact with mechanical loading and aging; therefore, it may be fruitful to evaluate such interactions with potentially causative *SLC1A3* SNPs in future studies.

EPHB2: Our findings suggest that regulation of the *Ephb2* gene contributes to the previously reported associations with BMD and fracture at the 1p36.12 locus. *ZBTB40* has been consistently linked to both spine and hip BMD as well as fracture risk(8,35-37) but has an unknown role in bone development or maintenance. *ZBTB40* was expressed in osteoblasts in our study, but the associated (intergenic) SNP was unrelated to any regulatory element in ENCODE. This gene is often reported concurrently with *WNT4* associations with BMD; however, LD patterns and conditional analyses support the existence of two separate signals in this region of chromosome 1p36.12(8). In addition, cis-eQTL analysis did not find significant associations between GWAS SNPs and *ZBTB40* and *WNT4* gene expression in whole bone. On the other hand, a cis-eQTL in this locus was found for the *EPHB2* gene. The *EPHB2* gene encodes a member of the Eph receptor family of receptor tyrosine kinase transmembrane glycoproteins. Several *in vitro* and animal studies have found that *Ephb2* is involved in bone development,(45) homeostasis,(46) and fracture repair(47), as well as skeletal response to PTH(48) and IGF(49). This is the first study to link genetic variation in humans to *EPHB2* expression and clinically important vertebral phenotypes.

GREM2: One additional locus associated with trabecular vBMD, an intronic SNP, rs9661787, in *FMN2* and near *GREM2*, has not previously been reported for lumbar spine BMD by DXA. It has, however, been linked to trabecular BMD of the distal tibia, as measured by peripheral quantitative CT (pQCT), and was demonstrated to affect trabecular number and thickness as evaluated by HRpQCT.(50) In the current analyses, the *FMN2/GREM2* SNP was also associated with integral vBMD with a similar effect size, perhaps because of the sizeable contribution of trabecular vBMD in the overall measure of integral vBMD by CT of the lumbar spine. The homologous region in mice (174.8 Mb on Chromosome 1) has consistently been associated with BMD phenotypes, including vertebral BMD.(51) In addition, our GWAS SNP rs9661787 in the *FMN2/GREM2* locus is in high LD ($r^2=0.88$) with a GWAS SNP (rs9287237) identified previously for a pQCT GWAS.(50) SNP

rs9287237 had similar effect sizes to our top SNP for trabecular vBMD and integral vBMD in this study.

SNP rs9287237 was robustly associated with *GREM2* expression in human osteoblasts.(50) Each additional T allele of rs9287237 was associated with decreased expression of *GREM2* in human osteoblasts, increased trabecular BMD and decreased fracture risk.(50) In our eQTL analysis, we also found SNP rs9287237 was associated with lower *GREM2* expression in human whole bone biopsies, though the association was not statistically significant. *GREM2* (aka *PRDC* and *Gremlin2*) is an extracellular antagonist of bone morphogenetic proteins (BMPs), and loss of this factor allows for an increase in osteoblastic differentiation.(52-54) We observed a marked decrease in expression of *Grem2* as these cells transitioned from a committed but immature cell to a fully mature osteoblast in mouse. This suggests that *Grem2* is an inhibitor of osteoblast maturation and/or function and that expression of this gene must be reduced to allow this process to occur. Our observation that GWAS SNP rs9661787 was associated with lower *GREM2* expression (Table 3) and associated with higher trabecular vBMD (Table 1, G allele of rs9661787) supports previous findings that *Grem2* inhibited osteoblast maturation and/or function. Available data suggest that this gene is not expressed or is only marginally expressed in mouse osteoclasts (<http://biogps.org>). Unlike for *Grem2*, expression of *Fmn2* was barely detectable in osteoblasts. This low/lack of expression of this gene in bone has been corroborated in other studies wherein whole bone, osteoblasts, osteoclast and osteoblast like cell lines were examined (<http://biogps.org>). Together these data suggest that *GREM2* is the more likely candidate at this locus.

Four other loci had common SNPs that were genome-wide significantly associated with trabecular vBMD (near *WNT4*, *ZBTB40*, *TNFRSF11B*, and *TNFSF11*), although effect sizes were much smaller than for the 5p13 locus. These loci have been consistently reported to be associated with lumbar spine BMD by DXA(8,28,29) and fracture.(10) The roles of *WNT4*, *TNFRSF11B*, and *TNFSF11* are well described in WNT-signaling and RANK/RANKL/OPG pathways, which are central to bone metabolism.(55) Of particular relevance to our phenotype of spine BMD in older age, *Wnt4* has been demonstrated to prevent bone loss and one of its common causes, inflammation, by inhibiting NF-κB in macrophages and osteoclast precursors.(56) The SNP, however, is predicted not to be constrained by SIFT and is benign by PolyPhen-2.

Phenotypic considerations

Volumetric BMD measured by CT has advantages over DXA BMD for evaluating genetic regulation specific to 3D structure and mineral density. CT measures allow for the removal of bone

size from the phenotype, whereas DXA BMD is a 2D measured combination of size and density. Furthermore, DXA BMD of the lumbar spine includes the vertebral body and posterior elements, as well as other regions that are predisposed to degenerative changes. Volumetric BMD measures, including trabecular and integral BMD, were more strongly associated with prevalent vertebral fracture than was areal spine BMD in a case-control study nested in the Framingham Osteoporosis Study.(11) Therefore, vBMD may be a more relevant phenotype for vertebral fracture risk. Although candidate gene analyses have discovered distinct associations with, e.g., vBMD and vertebral cross-sectional area(57), ours is the first GWAS of volumetric phenotypes in a multi-cohort meta-analysis and the first to link vBMD SNP associations to fracture and gene expression.

Limitations

Limitations of the study include a relatively small number (15,275) of participants with volumetric BMD phenotypes available. As a polygenic and complex trait, BMD requires very large sample sizes to detect the effect sizes often observed for common SNPs. Of 49 loci associated with lumbar spine BMD in previous large GWAS meta-analyses,(8,29) we identified only 9 in our volumetric spine BMD traits. Whether this lack of confirmation of previously identified spine BMD associations is due to true phenotypic differences in association or simply lower sample size in the current study is unknown. However, 4 out of 6 trabecular vBMD GWAS loci found in the current study have been reported by previous BMD GWAS meta-analysis; and 4 out 6 trabecular vBMD suggestive GWAS loci have also been reported by a previous DXA-derived BMD GWAS meta-analysis, suggesting limited statistical power with relatively smaller sample size may play a major role in this lack of confirmation. Further investigation of the involvement of those GWAS loci unique to the CT BMD will improve our understanding of the molecular regulation of bone.

Moderate effect size for most of the common SNPs may also contribute to the limited statistical power that the current study has. The majority of common variants previously reported are closer to zero ($|\text{standardized } \beta| \leq 0.03$) than the range of effect sizes we observed for GWS associations with volumetric BMD ($0.057 \leq |\text{standardized } \beta| \leq 0.098$), implying lack of power in this study to identify common SNPs with smaller effect sizes. Similarly, the study was not designed to detect less common ($1\% < \text{MAF} < 5\%$) or rare variants ($\text{MAF} < 1\%$), and only two variants with $2\% \leq \text{MAF} < 5\%$ (*SLC1A3* and *CTIF*) were found to be associated with trabecular vBMD or integral vBMD. These had effect sizes approximately three times as large as the more common variants and were similar in effect size to that reported for a low-frequency variant in *ENI* for vertebral BMD,(29) again underscoring the value of studying less common variants for skeletal phenotypes. There are undoubtedly other genetic

contributors to BMD that will require studies powered to detect moderate effect sizes in low-frequency or rare variants.

Limitations regarding heterogeneous radiographic vertebral fracture definitions have been described(9) and may have limited our power for observing fracture associations among the vertebral-BMD associated loci. However, we observed similar prevalence of fracture across the cohorts that were included (16-22%), indicating that differences in case definitions may result in ascertainment of similar cases in these studies. Three trabecular vBMD loci (near *ZBTB40*, *FMN2/GREM2*, and *SLC1A3*) were associated more strongly with clinical vertebral fracture than with radiographic vertebral fracture, indicating a potential for clinical fracture to give a stronger association signal than radiographic fracture for these variants.

Several additional limitations of this study include limited statistical power to detect SNPs with moderate eQTL; imputation based on HapMap II reference panel rather than whole genome sequencing based 1000G reference panel, providing limited coverage of genetic variants across genomes; and limited bone-relevant tissues in existing databases for the *in silico* annotations of associated loci. In addition, pinpointing causal variants and functionally validating them in cellular or animal models remain to be done.

Despite these limitations, we identified novel vertebral BMD and fracture associations related to *SLC1A3* and *EPHB2* expression. We also confirmed the importance of *GREM2* and several genes involved in WNT-signaling for trabecular BMD and vertebral fracture in large cohorts of older adults. Our study reinforces the benefit of large-scale GWAS of more refined and clinically relevant skeletal phenotypes and the need for continued evaluation of noncoding genomic variants with potential regulatory function.

References

1. Kendler DL, Bauer DC, Davison KS, Dian L, Hanley DA, Harris ST, McClung MR, Miller PD, Schousboe JT, Yuen CK, Lewiecki EM 2015 Vertebral fractures: clinical importance and management. *Am J Med* **129**(2):221.e1-221.e10.
2. Oudshoorn C, Hartholt KA, Zillikens MC, Panneman MJ, van der Velde N, Colin EM, Patka P, van der Cammen TJ 2012 Emergency department visits due to vertebral fractures in the Netherlands, 1986-2008: steep increase in the oldest old, strong association with falls. *Injury* **43**(4):458-61.
3. Leslie WD, Sadatsafavi M, Lix LM, Azimaee M, Morin S, Metge CJ, Caetano P 2011 Secular decreases in fracture rates 1986-2006 for Manitoba, Canada: a population-based analysis. *Osteoporos Int* **22**(7):2137-43.
4. Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ, 3rd 2014 Trends in fracture incidence: a population-based study over 20 years. *J Bone Miner Res* **29**(3):581-9.
5. Perilli E, Briggs AM, Kantor S, Codrington J, Wark JD, Parkinson IH, Fazzalari NL 2012 Failure strength of human vertebrae: prediction using bone mineral density measured by DXA and bone volume by micro-CT. *Bone* **50**(6):1416-25.
6. Liu CT, Karasik D, Zhou Y, Hsu YH, Genant HK, Broe KE, Lang TF, Samelson EJ, Demissie S, Bouxsein ML, Cupples LA, Kiel DP 2012 Heritability of prevalent vertebral fracture and volumetric bone mineral density and geometry at the lumbar spine in three generations of the Framingham study. *J Bone Miner Res* **27**(4):954-8.
7. Richards JB, Zheng HF, Spector TD 2012 Genetics of osteoporosis from genome-wide association studies: advances and challenges. *Nat Rev Genet* **13**(8):576-88.
8. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, Oei L, Albagha OM, Amin N, Kemp JP, Koller DL, Li G, Liu CT, Minster RL, Moayyeri A, Vandenput L, Willner D, Xiao SM, Yerges-Armstrong LM, Zheng HF, Alonso N, Eriksson J, Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG, Wilson JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR, Dailiana Z, Duggan DJ, Garcia M, Garcia-Giralt N, Giroux S, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Khusainova R, Kim GS, Kooperberg C, Koromila T, Kruk M, Laaksonen M, Lacroix AZ, Lee SH, Leung PC, Lewis JR, Masi L, Mencej-Bedrac S, Nguyen TV, Nogues X, Patel MS, Prezeli J, Rose LM, Scollen S, Siggeirsdottir K, Smith AV, Svensson O, Trompet S, Trummer O, van Schoor NM, Woo J, Zhu K, Balcells S, Brandi ML, Buckley BM, Cheng S, Christiansen C, Cooper C, Dedoussis G, Ford I, Frost M, Goltzman D, Gonzalez-Macias J, Kahonen M, Karlsson M, Khusnutdinova E, Koh JM, Kollia P, Langdahl BL, Leslie WD, Lips P, Ljunggren O, Lorenc RS, Marc J, Mellstrom D, Obermayer-Pietsch B, Olmos JM, Pettersson-Kymmer U, Reid DM, Riancho JA, Ridker PM, Rousseau F, Slagboom PE, Tang NL, et al. 2012 Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* **44**(5):491-501.
9. Oei L, Estrada K, Duncan EL, Christiansen C, Liu CT, Langdahl BL, Obermayer-Pietsch B, Riancho JA, Prince RL, van Schoor NM, McCloskey E, Hsu YH, Evangelou E, Ntzani E, Evans DM, Alonso N, Husted LB, Valero C, Hernandez JL, Lewis JR, Kaptoge SK, Zhu K, Cupples LA, Medina-Gomez C, Vandenput L, Kim GS, Hun Lee S, Castano-Betancourt MC, Oei EH, Martinez J, Daroszewska A, van der Klift M, Mellstrom D, Herrera L, Karlsson MK, Hofman A, Ljunggren O, Pols HA, Stolk L, van Meurs JB, Ioannidis JP, Zillikens MC, Lips P, Karasik D, Uitterlinden AG, Styrkarsdottir U, Brown MA, Koh JM, Richards JB, Reeve J, Ohlsson C, Ralston SH, Kiel DP, Rivadeneira F 2014 Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. *Bone* **59**:20-7.
10. Richards JB, Kavvoura FK, Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Zillikens MC, Wilson SG, Mullin BH, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra BA, Pols HA, Sigurdsson G, Thorsteinsdottir U, Soranzo N, Williams FM, Zhou Y, Ralston SH, Thorleifsson G, van Duijn CM, Kiel DP, Stefansson K, Uitterlinden AG, Ioannidis JP, Spector TD, Genetic Factors for Osteoporosis C 2009 Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. *Ann Intern Med* **151**(8):528-37.

11. Anderson DE, Demissie S, Allaire BT, Bruno AG, Kopperdahl DL, Keaveny TM, Kiel DP, Bouxsein ML 2014 The associations between QCT-based vertebral bone measurements and prevalent vertebral fractures depend on the spinal locations of both bone measurement and fracture. *Osteoporos Int* **25**(2):559-66.
12. Orwoll ES, Oviatt SK, Mann T 1990 The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men. *J Clin Endocrinol Metab* **70**(4):1202-7.
13. Li N, Li XM, Xu L, Sun WJ, Cheng XG, Tian W 2013 Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women. *Int J Endocrinol* **2013**:895474.
14. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, Thorgeirsson G, Aspelund T, Garcia ME, Cotch MF, Hoffman HJ, Gudnason V 2007 Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. *Am J Epidemiol* **165**(9):1076-87.
15. Samelson EJ, Christiansen BA, Demissie S, Broe KE, Louie-Gao Q, Cupples LA, Roberts BJ, Manoharam R, D'Agostino J, Lang T, Kiel DP, Bouxsein ML 2012 QCT measures of bone strength at the thoracic and lumbar spine: the Framingham Study. *J Bone Miner Res* **27**(3):654-63.
16. Budoff MJ, Hamirani YS, Gao YL, Ismaeel H, Flores FR, Child J, Carson S, Nee JN, Mao S 2010 Measurement of thoracic bone mineral density with quantitative CT. *Radiology* **257**(2):434-40.
17. Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, Lewis C, Cawthon PM, Marcus R, Marshall LM, McGowan J, Phipps K, Sherman S, Stefanick ML, Stone K 2005 Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. *Contemp Clin Trials* **26**(5):569-85.
18. Lang TF, Li J, Harris ST, Genant HK 1999 Assessment of vertebral bone mineral density using volumetric quantitative CT. *J Comput Assist Tomogr* **23**(1):130-7.
19. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res* **8**(9):1137-48.
20. Black DM, Cummings SR, Stone K, Hudes E, Palermo L, Steiger P 1991 A new approach to defining normal vertebral dimensions. *J Bone Miner Res* **6**(8):883-92.
21. Black DM, Palermo L, Nevitt MC, Genant HK, Epstein R, San Valentin R, Cummings SR 1995 Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. *J Bone Miner Res* **10**(6):890-902.
22. Cawthon PM, Haslam J, Fullman R, Peters KW, Black D, Ensrud KE, Cummings SR, Orwoll ES, Barrett-Connor E, Marshall L, Steiger P, Schousboe JT, Osteoporotic Fractures in Men Research G 2014 Methods and reliability of radiographic vertebral fracture detection in older men: the osteoporotic fractures in men study. *Bone* **67**:152-5.
23. Lange LA, Burdon K, Langefeld CD, Liu Y, Beck SR, Rich SS, Freedman BI, Brosnihan KB, Herrington DM, Wagenknecht LE, Bowden DW 2006 Heritability and expression of C-reactive protein in type 2 diabetes in the Diabetes Heart Study. *Ann Hum Genet* **70**(Pt 6):717-25.
24. Hsu FC, Lenchik L, Nicklas BJ, Lohman K, Register TC, Mychaleckyj J, Langefeld CD, Freedman BI, Bowden DW, Carr JJ 2005 Heritability of body composition measured by DXA in the diabetes heart study. *Obes Res* **13**(2):312-9.
25. Yang B, Sun H, Wang H 2010 The downstream effects of vitamin D in spermatozoa needs further study. *Hum Reprod* **25**(8):2152-3; author reply 2153.
26. Yang J, Lee SH, Goddard ME, Visscher PM 2011 GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* **88**(1):76-82.
27. Reppe S, Refvem H, Gautvik VT, Olstad OK, Hovring PI, Reinholt FP, Holden M, Frigessi A, Jemtland R, Gautvik KM 2010 Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. *Bone* **46**(3):604-12.
28. Hsu YH, Zillikens MC, Wilson SG, Farber CR, Demissie S, Soranzo N, Bianchi EN, Grundberg E, Liang L, Richards JB, Estrada K, Zhou Y, van Nas A, Moffatt MF, Zhai G, Hofman A, van Meurs JB, Pols HA, Price RI, Nilsson O, Pastinen T, Cupples LA, Lusi AJ, Schadt EE, Ferrari S, Uitterlinden AG, Rivadeneira F, Spector TD, Karasik D, Kiel DP 2010 An integration of genome-wide association study and gene

expression profiling to prioritize the discovery of novel susceptibility Loci for osteoporosis-related traits. *PLoS Genet* **6**(6):e1000977.

29. Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A, Leo PJ, Dahia CL, Park-Min KH, Tobias JH, Kooperberg C, Kleinman A, Styrkarsdottir U, Liu CT, Uggle C, Evans DS, Nielson CM, Walter K, Pettersson-Kymmer U, McCarthy S, Eriksson J, Kwan T, Jhamai M, Trajanoska K, Memari Y, Min J, Huang J, Danecek P, Wilmot B, Li R, Chou WC, Mokry LE, Moayyeri A, Claussnitzer M, Cheng CH, Cheung W, Medina-Gomez C, Ge B, Chen SH, Choi K, Oei L, Fraser J, Kraaij R, Hibbs MA, Gregson CL, Paquette D, Hofman A, Wibom C, Tranah GJ, Marshall M, Gardiner BB, Cremin K, Auer P, Hsu L, Ring S, Tung JY, Thorleifsson G, Enneman AW, van Schoor NM, de Groot LC, van der Velde N, Melin B, Kemp JP, Christiansen C, Sayers A, Zhou Y, Calderari S, van Rooij J, Carlson C, Peters U, Berlivet S, Dostie J, Uitterlinden AG, Williams SR, Farber C, Grinberg D, LaCroix AZ, Haessler J, Chasman DI, Giulianini F, Rose LM, Ridker PM, Eisman JA, Nguyen TV, Center JR, Nogues X, Garcia-Giralt N, Launer LL, Gudnason V, Mellstrom D, Vandenput L, Amin N, van Duijn CM, Karlsson MK, Ljunggren O, Svensson O, Hallmans G, Rousseau F, Giroux S, Bussiere J, Arp PP, et al. 2015 Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. *Nature* **526**(7571):112-7.
30. Consortium EP 2004 The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science* **306**(5696):636-40.
31. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ, Amin V, Whitaker JW, Schultz MD, Ward LD, Sarkar A, Quon G, Sandstrom RS, Eaton ML, Wu YC, Pfenning AR, Wang X, Claussnitzer M, Liu Y, Coarfa C, Harris RA, Shores N, Epstein CB, Gjoneska E, Leung D, Xie W, Hawkins RD, Lister R, Hong C, Gascard P, Mungall AJ, Moore R, Chuah E, Tam A, Canfield TK, Hansen RS, Kaul R, Sabo PJ, Bansal MS, Carles A, Dixon JR, Farh KH, Feizi S, Karlic R, Kim AR, Kulkarni A, Li D, Lowdon R, Elliott G, Mercer TR, Neph SJ, Onuchic V, Polak P, Rajagopal N, Ray P, Sallari RC, Siebenthal KT, Sinnott-Armstrong NA, Stevens M, Thurman RE, Wu J, Zhang B, Zhou X, Beaudet AE, Boyer LA, De Jager PL, Farnham PJ, Fisher SJ, Haussler D, Jones SJ, Li W, Marra MA, McManus MT, Sunyaev S, Thomson JA, Tlsty TD, Tsai LH, Wang W, Waterland RA, Zhang MQ, Chadwick LH, Bernstein BE, Costello JF, Ecker JR, Hirst M, Meissner A, Milosavljevic A, Ren B, Stamatoyannopoulos JA, Wang T, Kellis M 2015 Integrative analysis of 111 reference human epigenomes. *Nature* **518**(7539):317-30.
32. Ward LD, Kellis M 2012 HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res* **40**(Database issue):D930-4.
33. Ernst J, Kellis M 2012 ChromHMM: automating chromatin-state discovery and characterization. *Nat Methods* **9**(3):215-6.
34. Reppe S, Wang Y, Thompson WK, McEvoy LK, Schork AJ, Zuber V, LeBlanc M, Bettella F, Mills IG, Desikan RS, Djurovic S, Gautvik KM, Dale AM, Andreassen OA, Consortium G 2015 Genetic Sharing with Cardiovascular Disease Risk Factors and Diabetes Reveals Novel Bone Mineral Density Loci. *PLoS One* **10**(12):e0144531.
35. Duncan EL, Danoy P, Kemp JP, Leo PJ, McCloskey E, Nicholson GC, Eastell R, Prince RL, Eisman JA, Jones G, Sambrook PN, Reid IR, Dennison EM, Wark J, Richards JB, Uitterlinden AG, Spector TD, Esapa C, Cox RD, Brown SD, Thakker RV, Addison KA, Bradbury LA, Center JR, Cooper C, Cremin C, Estrada K, Felsenberg D, Gluer CC, Hadler J, Henry MJ, Hofman A, Kotowicz MA, Makovey J, Nguyen SC, Nguyen TV, Pasco JA, Pryce K, Reid DM, Rivadeneira F, Roux C, Stefansson K, Styrkarsdottir U, Thorleifsson G, Tichawangana R, Evans DM, Brown MA 2011 Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. *PLoS Genet* **7**(4):e1001372.
36. Karasik D, Myers RH, Hannan MT, Gagnon D, McLean RR, Cupples LA, Kiel DP 2002 Mapping of quantitative ultrasound of the calcaneus bone to chromosome 1 by genome-wide linkage analysis. *Osteoporos Int* **13**(10):796-802.
37. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson

- G, Kong A, Thorsteinsdottir U, Stefansson K 2008 Multiple genetic loci for bone mineral density and fractures. *N Engl J Med* **358**(22):2355-65.
38. Brakspear KS, Mason DJ 2012 Glutamate signaling in bone. *Front Endocrinol (Lausanne)* **3**:97.
39. Mason DJ, Suva LJ, Genever PG, Patton AJ, Steuckle S, Hillam RA, Skerry TM 1997 Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents? *Bone* **20**(3):199-205.
40. Gray C, Marie H, Arora M, Tanaka K, Boyde A, Jones S, Attwell D 2001 Glutamate does not play a major role in controlling bone growth. *J Bone Miner Res* **16**(4):742-9.
41. Schraven SP, Franz C, Ruttiger L, Lowenheim H, Lysakowski A, Stoffel W, Knipper M 2012 Altered phenotype of the vestibular organ in GLAST-1 null mice. *J Assoc Res Otolaryngol* **13**(3):323-33.
42. Courtland HW, Elis S, Wu Y, Sun H, Rosen CJ, Jepsen KJ, Yakar S 2011 Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner. *PLoS One* **6**(3):e14762.
43. Sabsovich I, Clark JD, Liao G, Peltz G, Lindsey DP, Jacobs CR, Yao W, Guo TZ, Kingery WS 2008 Bone microstructure and its associated genetic variability in 12 inbred mouse strains: microCT study and in silico genome scan. *Bone* **42**(2):439-51.
44. Zanotti S, Canalis E 2015 Activation of Nfatc2 in osteoblasts causes osteopenia. *J Cell Physiol* **230**(7):1689-95.
45. Raft S, Coate TM, Kelley MW, Crenshaw EB, 3rd, Wu DK 2014 Pou3f4-mediated regulation of ephrin-b2 controls temporal bone development in the mouse. *PLoS One* **9**(10):e109043.
46. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K 2006 Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. *Cell Metab* **4**(2):111-21.
47. Zhu L, Dissanayaka WL, Green DW, Zhang C 2015 Stimulation of EphB2/ephrin-B1 signalling by tumour necrosis factor alpha in human dental pulp stem cells. *Cell Prolif* **48**(2):231-8.
48. Takyar FM, Tonna S, Ho PW, Crimeen-Irwin B, Baker EK, Martin TJ, Sims NA 2013 EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. *J Bone Miner Res* **28**(4):912-25.
49. Wang Y, Menendez A, Fong C, ElAlieh HZ, Chang W, Bikle DD 2014 Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation. *J Bone Miner Res* **29**(8):1900-13.
50. Paternoster L, Lorentzon M, Lehtimäki T, Eriksson J, Kahonen M, Raitakari O, Laaksonen M, Sievanen H, Viikari J, Lyytikäinen LP, Mellström D, Karlsson M, Ljunggren O, Grundberg E, Kemp JP, Sayers A, Nethander M, Evans DM, Vandenput L, Tobias JH, Ohlsson C 2013 Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. *PLoS Genet* **9**(2):e1003247.
51. Ackert-Bicknell CL, Karasik D, Li Q, Smith RV, Hsu YH, Churchill GA, Paigen BJ, Tsai SW 2010 Mouse BMD quantitative trait loci show improved concordance with human genome-wide association loci when recalculated on a new, common mouse genetic map. *J Bone Miner Res* **25**(8):1808-20.
52. Ideno H, Takanabe R, Shimada A, Imaizumi K, Araki R, Abe M, Nifuji A 2009 Protein related to DAN and cerberus (PRDC) inhibits osteoblastic differentiation and its suppression promotes osteogenesis in vitro. *Exp Cell Res* **315**(3):474-84.
53. Im J, Kim H, Kim S, Jho EH 2007 Wnt/beta-catenin signaling regulates expression of PRDC, an antagonist of the BMP-4 signaling pathway. *Biochem Biophys Res Commun* **354**(1):296-301.
54. Suzuki D, Yamada A, Aizawa R, Funato S, Matsumoto T, Suzuki W, Takami M, Miyamoto Y, Suzawa T, Yamamoto M, Baba K, Kamijo R 2012 BMP2 differentially regulates the expression of Gremlin1 and Gremlin2, the negative regulators of BMP function, during osteoblast differentiation. *Calcif Tissue Int* **91**(1):88-96.
55. Baron R, Kneissel M 2013 WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med* **19**(2):179-92.
56. Yu B, Chang J, Liu Y, Li J, Kevork K, Al-Hezaimi K, Graves DT, Park NH, Wang CY 2014 Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-kappaB. *Nat Med* **20**(9):1009-17.
57. Zmuda JM, Yerges-Armstrong LM, Moffett SP, Klei L, Kammerer CM, Roeder K, Cauley JA, Kuipers A, Ensrud KE, Nestlerode CS, Hoffman AR, Lewis CE, Lang TF, Barrett-Connor E, Ferrell RE, Orwoll ES,

Osteoporotic Fractures in Men Study G 2011 Genetic analysis of vertebral trabecular bone density and cross-sectional area in older men. *Osteoporos Int* **22**(4):1079-90.

Table 1. Summary of associations with trabecular volumetric BMD (vBMD)

Locus	Position (build 36)	SNP	Nearest gene(s) (distance in kb) ¹	A1/A2	A1 frequency	Beta for A1	SE	Hetero- geneity I ²	P value		
									Discovery (N=12,287)	Combined (N=15,275) ²	
Combined $p < 5 \times 10^{-8}$ for trabecular vBMD											
1p36.12	22444772	rs12755933	<i>WNT4</i> (103)	C/G	0.27	-0.084	0.013	0	2.66×10^{-10}	9.80×10^{-11}	
1p36.12	22554953	rs12742784	<i>ZBTB40</i> (96)	C/T	0.21	0.094	0.015	0	1.18×10^{-10}	1.05×10^{-10}	
1q43	238659259	rs9661787	<i>FMN2</i> (0)- <i>GREM2</i> (60)	C/G	0.81	-0.098	0.015	0	1.26×10^{-10}	1.29×10^{-11}	
5p13	36516441	rs2468531	<i>SLC1A3</i> (126)- <i>RANBP3L</i> (179)	G/C	0.03	0.221	0.037	0	1.47×10^{-9}	1.91×10^{-8}	
8q24	120045437	rs1485303	<i>TNFRSF11B</i> (12)	A/G	0.44	-0.057	0.012	14.6	7.35×10^{-7}	4.63×10^{-9}	
13q14	41862203	rs17457561	<i>AKAP11</i> (67) (<i>TNFSF11</i> [700])	A/G	0.25	-0.095	0.014	0	1.95×10^{-12}	1.12×10^{-11}	
Combined $5 \times 10^{-8} \leq p < 5 \times 10^{-6}$ for trabecular vBMD											
2p21	54735125	rs2941584	<i>SPTBN1</i> (0)	C/T	0.32	-0.060	0.012	33.5	1.26×10^{-6}	1.29×10^{-7}	
6q25	151897286	rs10872673	<i>C6orf97</i> (40)	G/T	0.60	0.065	0.012	0	5.92×10^{-8}	8.22×10^{-7}	
12p13.3	2378832	rs7301013	<i>CACNA1C</i> (298)	A/G	0.83	-0.076	0.016	39.4	1.45×10^{-6}	4.90×10^{-7}	
12p12.1	28183168	rs12813778	<i>CCDC91</i> (118)- <i>PTHLH</i> (167)	A/G	0.23	-0.068	0.014	32.9	1.16×10^{-6}	2.35×10^{-6}	
12q21.3	88861177	rs4842697	<i>ATP2B1</i> (287)	G/T	0.57	-0.057	0.012	22.4	9.09×10^{-7}	2.60×10^{-6}	
16p13.3	315783	rs9921222	<i>AXIN1</i> (27)	C/T	0.47	-0.059	0.012	0	6.09×10^{-7}	4.90×10^{-7}	

¹ Locus zoom plots are in Supplemental Figure 3.

² Observations were added by new genotyping in AGES (n=2,021) and/or by in silico replication in DHS (n=967). The SNP association was considered to be replicated if the addition of the replication sample to the meta-analysis did not result in a $p > 5 \times 10^{-8}$.

Table 2. Associations with vertebral fracture for SNPs with combined $p < 5 \times 10^{-6}$ for trabecular volumetric BMD (vBMD)

			Morphometric vertebral fracture (N=21,701)					Clinical vertebral fracture (N=5,893)				
Locus	SNP	Nearest gene(s)	A1 frequency	OR	P value	FDR P value	Hetero- geneity I ²	A1 frequency	OR	P value	FDR P value	Hetero- geneity I ²
Combined $p < 5 \times 10^{-8}$ for trabecular vBMD												
1p36.12	rs12755933	WNT4	0.26	0.99	0.680	0.816	0	0.27	1.02	0.707	0.943	9.8
1p36.12	rs12742784	ZBTB40	0.20	0.99	0.798	0.826	10.2	0.20	0.82	6.2 x 10⁻⁵	7.4 x 10⁻⁴	5.4
1q43	rs9661787	FMN2-GREM2	0.82	1.06	0.102	0.306	48.7	0.82	1.12	0.055	0.220	0.1
5p13	rs2468531	SLC1A3-RANBP3L	0.03	0.75	0.001	0.012	0	0.03	0.66	0.011	0.066	5.3
8q24	rs1485303	TNFRSF11B	0.43	1.03	0.298	0.596	0	0.44	0.98	0.690	0.943	37.7
13q14	rs17457561	AKAP11	0.24	1.02	0.516	0.788	0	0.27	0.95	0.343	0.686	0.0
Combined $5 \times 10^{-8} \leq p < 5 \times 10^{-6}$ for trabecular vBMD												
2p21	rs2941584	SPTBN1	0.31	1.03	0.215	0.516	0	0.33	1.08	0.096	0.230	18.2
6q25	rs10872673	C6orf97	0.59	0.94	0.012	0.072	0	0.59	1.02	0.608	0.943	0.0
12p13.3	rs7301013	CACNA1C	0.84	1.01	0.826	0.826	0	0.85	1.02	0.792	0.950	0.0
12p12.1	rs12813778	CCDC91-PTHLH	0.23	0.98	0.525	0.788	75.7	0.24	1.10	0.081	0.230	0.0
12q21.3	rs4842697	ATP2B1	0.59	1.05	0.038	0.152	47.0	0.59	1.00	0.948	0.981	0.0
16p13.3	rs9921222	AXIN1	0.47	1.01	0.647	0.816	0	0.47	1.00	0.981	0.981	27.8

OR: odds ratio, FDR: false-discovery rate

Table 3. Summary of associations with gene expression in human bone biopsies

Locus	Position (build 36)	SNP	Region	Nearest gene(s) (distance in kb)	Association with the nearest genes		Gene	The most significant cis-eQTL			
					Beta	P value		Beta	P value	FDR P value	Distance (kb)
Combined $p < 5 \times 10^{-8}$ for trabecular vBMD											
1p36.12	22444772	rs12755933	intergenic	<i>WNT4</i> (103)	0.030	0.37	<i>EPHB2</i>	-0.062	0.02	0.34	465
1p36.12	22554953	rs12742784	intergenic	<i>ZBTB40</i> (96)	0.105	0.08	<i>EPHB2</i>	0.120	3.49x10⁻⁵	1.72 x10⁻³	355
1q43	238659259	rs9661787	intronic	<i>FMN2</i> (0)	0.027	0.27	<i>GREM2</i>	-0.049	0.10	0.61	60
5p13	36516441	rs2468531	intergenic	<i>SLC1A3</i> (126)	0.279	4.36 x10⁻³	<i>SLC1A3</i>	0.279	4.36x10⁻³	0.01	126
			intergenic	<i>RANBP3L</i> (179)	-0.107						
8q24	120045437	rs1485303	intergenic	<i>TNFRSF11B</i> (12)	-0.019	0.61	<i>NOV</i>	-0.136	0.04	0.53	452
13q14	41862203	rs17457561	intergenic	<i>AKAP11</i> (67)	-0.068	0.03	<i>AKAP11</i>	-0.068	0.03	0.32	67
			intergenic	<i>TNFSF11</i> (700)	0.035	0.28					
Combined $5 \times 10^{-8} \leq p < 5 \times 10^{-6}$ for trabecular vBMD											
2p21	54735125	rs2941584	intronic	<i>SPTBN1</i>	0.039	0.20	<i>EML6</i>	0.096	3.33 x10⁻³	0.04	69
6q25	151897286	rs10872673	intronic	<i>C6orf97</i> (<i>CCDC170</i>)	-0.003	0.92	<i>MTHFD1L</i>	-0.090	0.03	0.28	433
			intergenic	<i>ESR1</i> (160)	0.040	0.07					
12p13.3	2378832	rs7301013	intronic	<i>CACNA1C</i>	0.056	0.17	<i>WNT5B</i>	0.280	1.81 x10⁻⁴	0.01	752
12p12.1	28183168	rs12813778	intergenic	<i>CCDC91</i> (118)	n.a.	n.a.	<i>STK38L</i>	-0.068	0.03	0.15	813
			intergenic	<i>PTHLH</i> (167)	-0.018	0.41					
12q21.3	88861177	rs4842697	intergenic	<i>ATP2B1</i> (287)	-0.093	0.02	<i>ATP2B1</i>	-0.093	0.02	0.13	287
16p13.3	315783	rs9921222	intronic	<i>AXIN1</i>	-0.033	0.27	<i>POLR3K</i>	0.102	2.57 x10 ⁻³	0.07	279

FDR: false-discovery rate

Figure 1. Cross-sectional view of the trabecular region of interest in the lumbar spine. Trabecular vBMD included this region only, while integral vBMD also included the cortical compartment. Both exclude the posterior elements that DXA measures of BMD incorporate, thus allowing CT measures to more precisely capture BMD of the vertebral body itself.

Reprinted from *Bone*, Vol 44(4), Engelke K, Mastmeyer A, Bousson V, Fuerst T, Laredo J-D, Kalender WA, "Reanalysis precision of 3D quantitative computed tomography (QCT) of the spine", 566-572, Copyright 2009, with permission from Elsevier.

Figure 2. Beta coefficients and 95% CI for the additive effect of rs2468531 (*SLC1A3*) on trabecular vBMD (top) and morphometric vertebral fracture (bottom). Detailed study-specific results are provided in Supplemental Table 7.